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Abstract
Implantable disks for glaucoma treatment were prepared by blending poly(ε-
caprolactone), PCL, poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene
oxide) and dorzolamide. Their in vivo performance was assessed by their ca-
pacity to decrease intraocular pressure (IOP) in normotensive and hyperten-
sive eyes. Drug mapping showed that release was complete from blend disks
and the low molecular weight (MW) PCL after 1 month in vivo. The high
MW PCL showed non-cumulative release rates above the therapeutic level
during 3 months in vitro. In vivo, the fibrous capsule formation around the
implant controls the drug release, working as a barrier membrane. Histologic
analysis showed normal foreign body reaction response to the implants. In
normotensive eyes, a 20 % decrease in IOP obtained with the disks during 1
month was similar to Trusopt R© eyedrops treatment. In hypertensive eyes,
the most sustained decrease was shown by the high MW PCL (40 % after 1
month, 30 % after 2 months). It was shown that the implants can lower IOP
in sustained manner in a rabbit glaucoma model.
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1. Introduction1
Glaucoma is a chronic condition that requires long-term treatment in2
order to stop progressive and irreversible blindness ([1]). Treatment of glau-3
coma focuses on preserving vision by slowing down damage to the optic nerve.4
Therapy aims at preventing further damage by lowering IOP (or ocular hy-5
pertension) and it usually consists of pharmaceutical treatment and laser6
or surgical procedures ([2]). It was shown that reducing IOP is effective in7
preventing disease progression in ocular hypertension, primary open angle8
glaucoma, and even in normal tension glaucoma ([3]).9
In most glaucoma patients, medical therapy consists of topical eyedrops10
and oral tablets. However, administration and compliance are often problem-11
atic. Eyedrops produce low ocular bioavailability ([4]), unnecessary systemic12
exposure ([5]) and have low patient compliance due to uncomfortable sensa-13
tions ([6]), as well as difficulty of instillation or forgetfulness ([7]). Two main14
strategies have already been used clinically to diminish such effects, namely15
gel forming (viscous) solutions ([8]) and controlled drug delivery systems16
(CDDS).17
CDDS in the form of intraocular implants can deliver therapeutically18
effective amounts of drugs to targeted ocular tissues over sustained period19
of time without significant ocular/systemic side effects ([9]). Thus, CDDS20
can extremely suitable for chronic diseases, which require a constant level21
of medication to be maintained in the body over a long period of time.22
The major motivation for development and use of these devices is that they23
eliminate the need to take multiple doses of a drug during the day or week,24
thereby improving patient compliance and therapy outcomes ([4]).25
In a previous work, implants based on poly(ε-caprolactone), PCL were26
prepared by solvent-casting, followed by dip-coating ([10]). Unfortunately,27
this preparation method is not reproducible and low drug loadings were28
achieved. High drug loads are needed for long term treatment of chronic29
diseases such as glaucoma. Moreover, the volume of such devices should be30
as small as possible in order to be easily introduced at the implantation site.31
Melt compression is a reproducible, easily scalable method of producing im-32
plants of different shapes and sizes ([11, 12]). In addition, compact implants33
can be obtained with small polymer-to-drug ratio, which enables high drug34
loads in a relatively small implant volume.35
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The objective of the present work was to prepare a drug loaded biodegrad-36
able implant designed to provide a localized, long-term (6 months to 2 years)37
sustained release of the drug, that can be used in the treatment of glaucoma.38
A subconjunctival placement of the implant is simple to perform because of39
easy access to the implantation area and low vascularization. PCL and Lutrol40
F 127, Lu were selected because they are both biocompatible, biodegradable41
and they can be easily processed by conventional polymer processing tech-42
niques ([13]). Moreover, they are commercially available, inexpensive and43
well characterised polymers. PCL is a slowly degradable polymer, while Lu44
can be used as a release modulator ([14, 15]). Two molecular weights of PCL45
were used because it was shown that molecular weight determines the time46
lag before erosion and the rate of bioerosion in vivo ([16]). The implantable47
drug loaded disks were prepared by melt compression and their performance48
in vivo was evaluated by assessing the capacity to lower IOP in normotensive49
and hypertensive rabbit eyes.50
2. Materials and methods51
2.1. Preparation of polymer disks52
Poly(ε-caprolactone) (PCL40, average Mw 65000 g/mol and PCL10, av-53
erage Mw 15000 g/mol, Sigma-Aldrich) and Lutrol F 127 (Lu, poly(ethylene54
oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide), 9000-14000 g/mol, 7055
% by weight of polyoxyethylene, BASF) films and dorzolamide hydrochloride56
(Chemos GmbH) loaded films (Lu/PCL: 13/87, 6/94, 0/100 % w/w) were57
prepared by solvent casting from acetone (UV grade, Sigma-Aldrich) at 4058
◦C, using a 15 % w/v total polymer concentration and 33.3 % w/w theoret-59
ical drug loading. Polymer sheets were fabricated by compression moulding60
of the polymer films in a stainless steel mould by applying a pressure of 201.561
kg/m2 for 20 minutes at 100◦C. The mould was subsequently cooled under62
a jet of cold water (20◦C) during 2 minutes. Discs of 4 mm diameter (1 mm63
thickness, 4-5 mg drug mass, 13-16 mg total mass) were punched from the64
polymer sheets. They were used as such in characterization tests. Prior to65
in vivo implantation, the discs were sterilized using UV radiation during 2066
minutes (at 254 nm) in a UV chamber (Camag UV cabinet).67
2.2. Disk characterization68
Differential scanning calorimetry (DSC) was carried out using a DSC69
Q100 equipment (TA Instruments) under nitrogen atmosphere (100 mL/min).70
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Samples with masses of approximately 5 mg were heated until 100◦C, at a71
heating rate of 10◦C/min. The relative crystallinity of the disks was cal-72
culated as previously described considering the melting enthalpy of 100 %73
crystalline PCL and 100 % crystalline Lu [15]. Thermogravimetric analysis74
(TGA) was carried out using a SDT Q 600 equipment (TA Instruments).75
Samples with masses of approximately 10 mg were heated until 600◦C, at a76
heating rate of 10◦C/min. The degradation temperature (Td) was determined77
at the onset point of the TGA plot.78
Water contact angle was evaluated by static contact angle measurements79
using an OCA 20 Video-Based Contact Angle Meter (Dataphysics) and em-80
ploying the sessile drop method.81
Drug loading of the disks was assessed by elemental analysis (quantifica-82
tion of sulphur, present only in the drug molecule).83
2.3. Morphology and drug distribution84
The morphology of the disks (before and after implantation) was exam-85
ined using scanning electron microscopy, SEM (JSM 5310, Jeol). The drug86
mapping (elemental sulphur) of the disks surface and cross-section (showing87
the center of the disk) was done using electron probe microanalysis, EPMA88
(Camebax SX50, Cameca) at 15 kV accelerated voltage and 40 nA probe89
current.90
2.4. In vitro and in vivo degradation91
The extent of hydrolytic degradation of the disks (as prepared, in vitro92
degraded and in vivo degraded) was evaluated by determining the change93
of MW in time. Polymer disks were placed in 4 mL PBS with 0.001 %94
sodium azide, at 37◦C. The changes in the MW were measured by size ex-95
clusion chromatography (SEC), using chloroform as mobile phase (1 ml/min,96
30 ◦C) and a PLgel MIXED-C column (300 mm×7.5 mm, 5 µm, Varian).97
PL-EMD 960 (Polymer Laboratories) evaporative light scattering detector98
was used to acquire the data. Universal calibration was performed us-99
ing polystyrene (PS) standards and Mark-Houwink parameters kPCL=1.09100
×10−3 dl/g, αPCL=0.60, kPS=1.25 ×10
−4 dl/g, αPS=0.71. Peak integration101
was performed using Clarity chromatography software (DataApex).102
2.5. In vitro drug release and release modelling103
Dorzolamide hydrochloride release was studied in 10 ml phosphate saline104
buffer medium (PBS tablets, pH 7.4, 10 mM phosphate, 137 mM sodium,105
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2.7 mM potassium, Sigma-Aldrich) at 37◦C. At scheduled time intervals,106
samples were taken and the entire medium volume was replaced with fresh107
medium to maintain sink conditions. The mass of dorzolamide hydrochloride108
released at time t was determined by UV spectroscopy at 254 nm (Jasco109
V-650 Spectrophotometer). The percentage of in vitro released drug was110
calculated using Eq.1.111
Released drug in vitro (%) =
Mdt
Md0
× 100 (1)
In Eq. 1, Mdt is the drug mass released at time t and Md0 is the initial drug112
mass.113
In order to study the drug release mechanism, the power law equation114
(Eq.2) which is based on diffusional model of drug transport, was used, where115
Mt/Mtotal is the fractional release of the drug, k is the kinetic constant and116
n is the release exponent, indicating the mechanism of drug release [15].117
Mt
Mtotal
= k tn (2)
An alternative model (Eq.3) based on polymer degradation control of118
drug release was used to fit the release data. In this model, two pools of119
drug are considered: a pool of mobile drug which readily diffuses out of the120
matrix upon immersion in an aqueous medium and a pool of immobilized121
drug which can diffuse only after matrix degradation [15]. This model can122
be applied to slow-degrading polymers such as PCL due to the fact that123
polymer degradation is much slower than drug diffusion and as such it is the124
rate limiting step for drug transport.125
M(τ) = A0 + |Ω|S0 (1− exp (−τ)), α¯
−1
lmn → 0 (3)
In Eq. 3, A0 is the load of the mobile drug, S0 is the load of immobilized126
drug, τ is the dimensionless time and is defined by τ = µ t (µ is the degrada-127
tion rate constant) and Ω is the geometrical factor. The model parameters128
were determined by non-linear regression and the goodness of the fit was129
assessed.130
2.6. Disk implantation, glaucoma model, intraocular pressure measurement131
and in vivo drug release132
New Zealand white rabbits were used in animal experiments in agree-133
ment with European Union Council Directive 86/609/EEC regarding the134
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protection of animals used for experimental and other scientific purposes as135
described before ([10]). The disk implantation procedure and the IOP mea-136
surement by tonometry were already described ([10]). In order to produce137
high IOP, we used a low temperature ophthalmic cautery (Bovie, Aaron Med-138
ical) to produce 30 to 50 burns that were directed at the limbal plexus and139
at the episcleral veins ([17, 18]).140
The animals were divided in three groups: group 1 (n=26) received drug141
loaded polymer disks (the right eye contained the drug loaded disk–PCL40,142
PCL10, 6%Lu,PCL40 and 13%Lu,PCL40, while the left had the control disk–143
polymers without drug), group 2 (n=3) was submitted to Trusopt R© eyedrops144
(dorzolamide hydrochloride 2 %, Chibret) treatment (1 drop twice a day in145
the right eye, while the left eye received a drop of balanced salt solution,146
BSS sterile solution, Alcon), while group 3 (n=3) was the glaucoma model147
reference.148
For in vivo release tests, previously weighed polymer disks were implanted149
as described before for predetermined periods of time and subsequently re-150
moved, cleaned of ocular tissues, rinsed with distilled water and vacuum-dried151
to constant weight. The in vivo released mass of drug was determined gravi-152
metrically using Eq. 4. In Eq. 4, Mi is the initial disk mass, Mt is the disk153
mass after implantation time t, Mc is the mass loss of the control disk and154
Md0 is the initial drug mass.155
Released drug in vivo (%) =
Mi −Mt −Mc
Md0
× 100 (4)
In vivo drug released percentages were also determined by elemental anal-156
ysis (the residual drug was determined after in vivo implantation).157
2.7. Histologic evaluation158
The local implant site and important organs were excised for histological159
evaluation. The collected organs included kidneys, spleen, liver, lung (only160
after 2 months implantation). The organs and tissue samples were fixed in161
10 % neutral buffered formaldehyde. The samples were then embedded in162
paraffin and dehydrated by isopropanol processing. Thin layers were cut163
from the samples with a microtome and stained with hematoxylin and eosin164
for optical microscopy.165
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Sample Td (
◦C) Tm (
◦C) Contact angle (deg)
PCL40+drug 279.38, 420.20 61.53 (0.03) 80.23 (2.63)
PCL40 375.51 61.26 (0.31) 73.88 (3.31)
PCL10+drug 275.00, 420.33 60.67 (0.19) 78.26 (1.24)
PCL10 269.62, 421.88 61.23 (0.61) 70.24 (1.86)
6%Lu,PCL40+drug - 61.45 (0.42) 46.87 (2.78)
6%Lu,PCL40 - 62.07 (0.17) 32.52 (2.12)
13%Lu,PCL40+drug - 58.22 (0.26) 39.88 (0.80)
13%Lu,PCL40 - 58.86 (0.45) 40.20 (2.53)
Lu 358.80 55.57 (0.65) 59.33 (0.35)
Table 1: Water contact angle, melting and degradation temperatures of the disks
2.8. Statistics166
All values are presented as mean and standard error of the mean (SEM).167
Experiments were performed in triplicates. Statistical analysis (Student’s168
T-test, independent, two-tailed) was done using OpenOffice.org Calc 3.1.169
3. Results and discussion170
3.1. Disk characterization171
In Table 1, melting (Tm) and degradation temperatures (Td) are presented172
for drug loaded and control disks because their knowledge is required when173
dealing with polymer processing methods for the manufacture of drug-eluting174
implants. Blend disks are more hydrophilic than PCL disks due to the in-175
corporation of hydrophilic Lu ([14, 15]) as shown by the lower contact angle176
values. The low Tm enables processing at temperatures much lower than the177
degradation temperature of dorzolamide (Td=251.26
◦C). The PCL samples178
show a two step degradation process, the first step corresponding to drug179
degradation, while the second corresponds to polymer degradation.180
All disks presented an average content of sulphur of 33.6 %, which corre-181
sponds to approximately 5 mg of loaded drug in each disk.182
3.2. General considerations about implantation surgical procedure and animal183
wellbeing184
The surgical procedure to insert the disks is relatively easy to perform185
because of easy access to the implantation area and low vascularization.186
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Moreover, the wound does not need to be sutured because a pocket is cre-187
ated that keeps the disk in place. The fixation of the disk is further enhanced188
by fast wound healing as the disk is completely encapsulated by the conjunc-189
tiva. Ocular adverse events included conjunctivitis (6 eyes in 64 eyes), that190
resolved clinically in less than 1 week (with antibiotic eyedrops). No other191
events were observed. It should be mentioned that such ocular adverse events192
(conjunctival hyperemia, stinging, burning, foreign body sensation, tearing,193
vision blurring) are quite frequent in topical treatment with eyedrops [6].194
3.3. In vitro and in vivo drug release195
Each disk was loaded with approximately 5 mg of drug in order to achieve196
a release rate of 18 µg/day (similar with the one obtained with Trusopt R©197
2% instillation three times a day [19]) for at least 4.5 months (we considered198
50 % drug losses during the transport from conjunctiva to cilliary body).199
Fig. 1(a) presents the release from blends: release is almost complete200
after 10 days for 13%Lu,PCL40 and after 20 days for 6%Lu,PCL40. The201
release kinetics shown in Fig. 1(b) presents similar released drug percentages202
regardless of the PCL molecular weight.203
A comparison between released drug percentages in vitro and in vivo204
is shown in Table 2. It can be noted that there are significant differences205
between released percentages in vitro and in vivo for PCL40 and PCL10206
samples (p=0.07 and p=0.01, respectively), while the released drug percent-207
ages of 6%Lu,PCL40 and 13%Lu,PCL40 are similar in vitro and in vivo208
(p=0.15 for 6%Lu,PCL40). In vivo drug released percentages (calculated by209
mass balance) for PCL40 implant were confirmed by elemental analysis (the210
residual drug was determined after in vivo implantation): after 8 days, 22.69211
(5.82) % released drug, after 14 days, 24.09 (2.93) % released drug and after212
22 days 35.74 (11.54) % released drug.213
In vivo release kinetics (Fig. 1(c)) seems to approach a zero-order kinetics,214
while the in vitro kinetics curves (Fig. 1(b)) appear to have a t0.5 profile.215
This may be due to different release controlling phenomena: in vitro, diffusion216
controls drug release (from here the classic, Fickian t0.5 profile), while in vivo,217
the fibrous capsule formation around the implant (see section 3.7) controls218
the drug release, functioning as a barrier membrane that slows down release.219
Thus, there should be significant differences between drug released in vitro220
and in vivo (see Table 2) for PCL40 and PCL10 samples. For blend samples,221
due to polymer erosion that takes place mostly in the first day of release222
[15], the fibrous capsule/barrier control is absent (only after 1 week, the223
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(a) (b)
(c)
Figure 1: a), b) In vitro drug release (the red arrow indicates the point on the kinetics
curve when the released dose is smaller than the effective dose), c) Comparison between
in vivo and in vitro drug release for sample PCL40
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Sample In vitro In vivo
Rel. drug (%) Rel. drug mass (mg) Rel. drug (%)
1
month
2
months
1
month
2
months
1
month
2
months
PCL40 40.14
(6.48)
51.88
(6.07)∗
2.22
(0.72)
3.72
(0.13)
42.99
(14.06)
72.02
(2.49)∗
PCL10 47.29
(0.96)∗
- 4.47
(0.18)
- 83.30
(4.01)∗
-
6%Lu,PCL40 90.98
(1.06)
- 4.74
(0.20)
- 96.80
(1.62)
-
13%Lu,PCL40 90.57
(3.79)
- 4.95 - 94.56 -
Table 2: Released drug percentages for in vitro tested disks and disks implanted during 1
month or 2 months (∗, p≤0.1 statistically significant differences between in vitro and in
vivo drug released percentages)
disks were fully encapsulated) and as such the released drug percentages are224
similar both in vitro and in vivo.225
In Table 3, the non-linear regression results are presented. The objec-226
tive behind fitting these equations to the release data was to understand227
the underlying phenomena involved in the drug release mechanism. Smaller228
values for S0 suggest higher amounts of immobilized drug that will not be229
released (37.8 % for PCL40 and 16.6 % for 13%Lu,PCL40). The percentage230
of immobilized drug is higher for PCL40 than for blend samples because in231
the latter case erosion creates more surface area and exposes more drug to232
water dissolution that otherwise would be trapped. In the case of the studied233
polymers, physical immobilization of the drug occurs due to drug entrapment234
in crystalline regions. Drug diffusion from these regions is hindered because235
water enters initially only in the amorphous parts. The immobilized fraction236
of the drug will be released only with polymer degradation (this explains237
why the steady state value of released drug percentage is smaller than 100238
%, which would correspond to total release).239
The regression results obtained using power law equation reinforce the240
previous observations. The high value of k indicates the extent of burst,241
higher for blend samples. The range of values for the release exponent is242
10
Sample Power law Degradation model
k
(day−n)
n R2adj A0 S0 µ
(day−1)
R2adj
PCL40 17.05
(0.65)
0.26
(0.01)
0.98 10.75
(1.42)
62.21
(1.64)
0.02
(0.00)
0.96
PCL10 24.11
(0.60)
0.19
(0.01)
0.97 15.86
(1.67)
51.45
(1.86)
0.04
(0.00)
0.92
6%Lu,PCL40 41.31
(3.14)
0.27
(0.03)
0.92 5.90
(1.33)
84.12
(1.46)
0.42
(0.03)
0.99
13%Lu,PCL40 56.23
(3.53)
0.17
(0.02)
0.83 7.01
(0.66)
83.41
(0.69)
1.66
(0.04)
1.00
Table 3: Model parameters determined by non-linear regression
indicative of a diffusion mechanism for drug release. This model fails to243
explain the last stage of the release (steady-state at less than 100 % released244
drug) as it doesn’t consider the effect of polymer degradation.245
The release kinetics suggested a three stage release mechanism, with246
different steps depending on disk composition. Dissolution of the surface247
loaded drug and subsequent diffusion, followed by diffusion of the mobile248
drug through water-filled pores (created either due to Lu leaching or poly-249
mer recrystallization [15, 20]), while the last stage was controlled by polymer250
degradation and subsequent diffusion of the immobilized drug. In blends,251
most of the drug is released due to polymer erosion, while the residual drug252
was released by diffusion through water-filled pores. The mechanism from253
PCL40/PCL10 disks and blend disks are essentially the same, except for the254
initial stage when drug diffusion is coupled with polymer erosion in the case255
of blends. By selecting the proper ratio between the components, the pre-256
ponderance of a certain stage during drug release can be changed, obtaining257
an overall effect in drug release that fits the intended application.258
3.4. Intraocular pressure measurement259
In order to simulate ocular hypertension, we developed a rabbit glaucoma260
model by increasing the IOP values (Fig. 2(d)) from an average of 20.9 mmHg261
(normotensive eyes) to an average of 30.1 mmHg (hypertensive eyes). A262
second procedure was performed after 1 month because IOP values returned263
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Sample Average IOP reduction (%)
Normotensive eyes Hypertensive eyes
1 month 1 month 2 months
Trusopt 16.55 (10.94) 25.21 (9.74) 23.82 (10.14)
PCL40 16.91 (6.43) 41.06 (12.16)∗ 33.21 (8.90)
PCL10 23.73 (8.15) 39.61 (11.90)∗ -
6%Lu,PCL40 23.85 (7.24) 39.24 (15.21)∗ -
13%Lu,PCL40 16.59 (8.02) - -
Table 4: Average IOP reduction (∗, p≤0.01 statistically significant differences between
IOP percentages obtained by disk implantation relative to those obtained with Trusopt
instillation)
to baseline after this period [17, 18]. Disks were first tested in normotensive264
eyes in order to select the best performing systems. In Fig. 2(e) and Fig. 2(f),265
it can be seen that sample 13%Lu,PCL40 decreased IOP by 16.6 % (see also266
Table 4) reaching the baseline value after 15 days, while sample 6%Lu,PCL40267
decreased IOP by 23.8 % during 25 days. More sustained decrease in IOP268
was shown by sample PCL40 (16.9 %) and PCL10 (23.7 %) during the 30269
days of test. The decrease in IOP obtained with the disks was comparable270
with the one obtained by applying Trusopt eyedrops (p≥0.17 for all disks).271
A decrease of at least 20% is desired in order to reduce the rate of open angle272
glaucoma-related damage [21].273
Fig. 2(a) and Fig. 2(b) present IOP change in hypertensive eyes with274
implanted disks and in eyes treated with Trusopt R© (Fig. 2(c)). PCL40275
presented a decrease of 41.1 % after 1 month and a decrease of 33.2 % after276
2 months, which is particularly suitable for patients with moderate to severe277
glaucoma [21]. IOP values in eyes with PCL40 implants are expected to278
approach the baseline values after approximately 3 months (see Fig. 1(b)).279
Samples PCL10 and 6%Lu,PCL40 showed similar IOP decrease percentages280
and peak IOP percentage in hypertensive eyes, while peak IOP was attained281
faster for sample 6%Lu,PCL40 due to faster drug release (see section 3.3).282
Thus, the release rate from the disks can be manipulated by blending in order283
to achieve the desired decrease in IOP.284
Table 4 presents the average IOP decrease percentages achieved by the285
implanted disks in normotensive and hypertensive eyes, while Table 5 shows286
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(a) (b)
(c) (d)
(e) (f)
Figure 2: a), b) IOP in hypertensive eyes of group undergoing implant treatment, c) IOP in
hypertensive eyes of group undergoing Trusopt R© eyedrops treatment, d) IOP in glaucoma
model group, e), f) IOP in normotensive eyes of group undergoing implant treatment (the
red arrow indicates the point when a second cauterization was performed)
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Sample Peak IOP reduction (%)/time (days)
Normotensive eyes Hypertensive eyes
1 month 1 month 2 months
Trusopt 27.85/0.96 36.59 (2.37)/3.38 35.33 (3.65)/34.56
PCL40 25.67/7.35 55.26 (0.98)/6.90 43.24 (2.55)/25.06
PCL10 35.92/6.90 50.21 (0.00)/6.94 -
6%Lu,PCL40 32.00/4.38 55.23 (5.03)/3.18 -
13%Lu,PCL40 29.96/2.42 - -
Table 5: Peak IOP and the time interval from instillation/implantation to peak IOP
the peak IOP decrease and the time interval from instillation/implantation287
to peak IOP. It can be noted that there was a higher IOP decrease in hy-288
pertensive eyes than in normotensive eyes for eyedrops and disks (p≤0.01289
for all disks). Sample PCL40 showed the best performance in vivo (constant290
decrease in IOP for longer time) due to more sustained drug release. The291
obtained values for IOP decrease with Trusopt R© are in agreement with litera-292
ture values for normotensive ([22, 23]) and hypertensive eyes ([24, 25]). There293
was a higher decrease in IOP for eyes treated with disks than in those treated294
with eyedrops (p≤0.01 for all disks) probably because of higher amounts of295
drug released by the disks (average in vitro release rate of 0.43 (0.04) mg/day296
for PCL40 or 1.34 (0.12) mg/day for PCL10 during 1 month versus 0.02297
mg/day delivered by eyedrops ([19])). The changes in IOP obtained in the298
eyes with implanted disk are similar to those obtained with the Ocusert drug299
delivery system ([26]). Trusopt R© eyedrops produced the fastest decrease in300
IOP in normotensive eyes with peak IOP attained after 0.96 days, followed by301
blend disks in agreement with in vitro release results (peak IOP was reached302
fastest for blend disks with higher content of Lu). In hypertensive eyes, the303
same trend in IOP decrease was maintained, but the average IOP and peak304
IOP values were higher than those obtained in normotensive eyes. Peak IOP305
occured at similar times in hypertensive eyes, except for Trusopt R©. Prob-306
ably, dorzolamide administered by eyedrops might require multiple doses to307
build up to steady state levels of concentration in the cilliary processes that308
are required for IOP decrease in hypertensive eyes.309
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(a) (b) (c)
(d) (e) (f)
Figure 3: SEM of disks (with drug) surface. a) PCL40 as prepared, b) PCL40 in vivo, c)
PCL10 as prepared, d) PCL10 in vivo, e) 6%Lu,PCL40 as prepared, f) 6%Lu,PCL40 in
vivo
3.5. Morphology and drug distribution, SEM and EPMA310
SEM and EMPA were performed in order to determine the morphology311
of the disks and the drug distribution inside the disks before and after the in312
vivo implantation.313
Fig. 3(a) to Fig. 3(f) show the surface morphology of the prepared disks314
and in vivo degraded disks. There are significant signs of degradation on the315
implanted disk surface such as pores (Fig. 3(b)), cracks (Fig. 3(d)) and scales316
(Fig. 3(f)). The in vitro degraded samples showed fewer signs of material317
cracking (images not shown). This suggested enhanced degradation in vivo318
in comparison with in vitro conditions (see section 3.7).319
After preparation, the disks presented a heterogeneous drug distribution320
(Fig. 4(a)) probably because of phase separation between drug and polymers321
due to the high drug loading. After in vivo testing, there was almost no drug322
at the surface (Fig. 4(b)), while in the disk cross-section there were still323
significant amounts of drug present in sample PCL40 after 1 month in vivo324
(Fig. 4(c)). The mapping of the other disks sections show that the release325
was complete after 1 month of implantation.326
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(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 4: Sulphur drug mapping after 1 month in vivo. a) PCL40 surface as prepared,
b) PCL40 surface in vivo, c) PCL40 section in vivo, d) PCL10 surface as prepared, e)
PCL10 surface in vivo, f) PCL10 section in vivo, g) 6%Lu,PCL40 surface as prepared, h)
6%Lu,PCL40 surface in vivo, i) 6%Lu,PCL40 section in vivo (in the scale bar, the colour
gradient represents 0% drug (pink) and 100% drug (red))
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3.6. In vitro and in vivo degradation327
To differentiate between a physical or a chemical degradation mecha-328
nism, the crystallinity and MW was determined for initial, in vitro and in329
vivo degraded samples (in section 6, the table 6 presents the change of disk330
crystallinity and MW due to in vitro and in vivo degradation). There was331
MW decrease due to chemical hydrolysis for PCL40+drug sample both after332
1 month and 2 months and for 6%Lu,PCL40+drug after 1 month. Sample333
PCL10+drug did not degrade in vivo probably due to higher initial crys-334
tallinity as crystalline regions are more inaccessible to water uptake. The335
MW of the in vitro degraded samples was also determined, but the obtained336
differences were not statistically significant (p≥0.17). The samples presented337
lower crystallinity than the pure polymers (50.26 (0.33) % for PCL40 and338
68.51 (2.12) % for Lu) and the drug loaded samples showed lower crystallinity339
than the control samples probably due to co-crystallization of dorzolamide340
(that is above the solubility limit in the polymer). In general, there was an341
increase in crystallinity for in vitro and in vivo degraded samples because the342
amorphous regions are degraded first and because during drug elution, the343
mobile polymer chains rearrange themselves and crystallize [15, 20]. Crys-344
tallinity was higher only for some in vivo degraded samples with respect to345
the in vitro degraded samples, suggesting that there is crystallinity increase346
and enhanced mechanical breakdown in vivo (see section 3.7).347
3.7. Histologic evaluation348
The tissue samples collected from various organs showed normal cell mor-349
phology. The histological analysis of the tissues from the implantation site350
showed rapid resolution of the acute and chronic inflammatory stages and351
the development of normal foreign body reaction, consisting of adherent352
macrophages (Fig. 5(b)), fibroblasts, lymphocytes and foreign body giant353
cells (Fig. 5(c)) on the surface of the disk and fibrous capsule formation354
(Fig. 5(d)). Blood vessels (Fig. 5(a)) that formed in the fibrous capsule355
were also observed. There was a higher density of cells on the drug loaded356
disk with respect to control disks. No acute and/or chronic inflammation357
was seen after 2 months, indicating that the disks were biocompatible and358
did not produce inflammatory reactions characteristic to toxic materials.359
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(a) (b)
(c) (d)
Figure 5: Light microscopy images of implanted disk showing a) cells and blood vessel
(shown in the ellipse); b) macrophage cells (highlighted by circles); c) foreign-body giant
cell; d) fibrous capsule
4. Conclusions360
Subconjunctival disks based on PCL and loaded with dorzolamide hy-361
drochloride were implanted in rabbit eyes and their in vivo performance was362
assessed by their capacity to lower IOP in normotensive and hypertensive363
eyes. The high MW PCL showed non-cumulative release rates above the364
therapeutic level during 3 months. Histologic analysis showed normal for-365
eign body reaction response consisting of adherent macrophages, fibroblasts,366
lymphocytes, foreign body giant cells and fibrous capsule formation. The367
release kinetics suggested a three stage release mechanism based on drug368
diffusion, polymer erosion and polymer degradation, with different steps de-369
pending on disk composition. In vivo, the fibrous capsule formation around370
the PCL implant controls the drug release, working as a barrier membrane.371
For blend disks, due to polymer erosion that takes place mostly in the first372
18
day of release, the fibrous capsule/barrier control is absent.373
In normotensive eyes, a 20 % decrease in IOP obtained with the disks374
during 1 month was comparable with the one obtained by applying Trusopt R©375
eyedrops. In hypertensive eyes, higher decrease percentages (around 40 %)376
were obtained for all samples, with the most sustained decrease from the377
high MW PCL (40 % after 1 month, 30 % after 2 months). Peak IOP378
occured earlier for blend disks due to enhanced drug release triggered by379
polymer erosion. It was proven that the devices can lower IOP in sustained380
manner in a rabbit glaucoma model. The blending offers the possibility to381
manipulate release rate and the amount of released drug in order to prepare382
devices tailored to the needs of patients (target IOP decrease percentages383
should take into account risk factors and disease progression).384
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Sample As
prepared
In vitro In vivo
Xrel (%) Xrel
(%)
mass
loss
(%)
Xrel
(%)
mass
loss
(%)
Mw (g/mole) ∆Mw (%)
1 month 1 month 1
month
2
months
1
month
2
months
PCL40+drug 36.97
(1.93)
29.13
(0.97)
13.46
(1.14)
38.89
(0.03)†
15.07
(4.93)
62377.5
(725.5)
60274.5
(112.4)
4.9∗ 8.1∗
PCL40 50.26
(0.33)
43.62
(1.27)
0.74
(0.11)
46.13
(1.62)
0.90
(0.07)
62727.3
(3555.6)
57653.5
(210.0)
4.4 12.1∗
PCL10+drug 40.06
(0.15)
42.26
(4.36)
22.68
(1.76)
50.66
(1.48)
30.75
(1.19)
16906.5
(2556.2)
- 10.8
PCL10 56.41
(0.34)
- 1.73
(0.42)
60.85
(1.51)
2.98
(0.21)
15152.5
(55.9)
- 0.7 -
6%Lu,PCL40+drug 32.12
(0.17)
38.51
(0.72)
36.77
(0.01)
47.18
(0.70)†
33.37
(0.48)
60625.5
(102.5)
- 7.6∗ -
6%Lu,PCL40 43.41
(0.19)
- 1.30
(0.10)
45.15
(1.79)
1.51
(0.14)
58144.5
(748.8)
- 11.4∗ -
13%Lu,PCL40+drug 30.32
(0.52)
41.43
(0.56)
41.12
(0.45)
44.07
(2.69)
37.36 61636.5
(2686.3)
- 6.0 -
13%Lu,PCL40 38.40
(1.13)
- 7.71
(0.56)
44.43
(2.96)
5.84 61606 - 6.1 -
Table 6: Crystallinity, mass loss and molecular weight evolution for in vitro and in vivo degraded samples (p≤0.05, ∗, relative
to initial MW, †, relative to in vitro crystallinity)
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